Searchable abstracts of presentations at key conferences in endocrinology

ea0089c4 | Clinical – Chemo/SSA/Biologics | NANETS2022

Cisplatin vs Carboplatin in Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas (PD NEC)

McLaughlin Nicole , McGarrah Patrick , Eiring Rachel , Leventakos Konstantinos , Sonbol Mohamad , Starr Jason , Hobday Timothy , Halfdanarson Thorvardur

Background: Extrapulmonary PD NECs carry a poor prognosis. Some studies suggest cisplatin is more appropriate for younger patients due to its increased potency and nephrotoxicity compared to carboplatin, but randomized trials are lacking. We aim to determine whether there is a difference in outcomes for cisplatin vs carboplatin while adjusting for possible confounding factors.Methods: We identified PD NEC patients at Mayo Clinic between 2000-2022. Kaplan...

ea0089c42 | Clinical – Surgery/Applied Pathology | NANETS2022

Small Intestinal NET Recurrence – When Why and How?

Pai Priya K. , Gudmundsdottir Hallbera , Cleary Sean P. , Halfdanarson Thorvardur R.

Background: Through this study, we hoped to better understand the factors affecting recurrence-free survival in patients who have undergone curative intent resection for small bowel neuroendocrine tumors (SB-NETs). Extensive literature exists on recurrence predictors for pancreatic NETs but not for those of the small bowel. We hope to bridge this gap.Methods: We retrospectively evaluated patients who had received their index curative-intent operation for...

ea0098c14 | Clinical – Chemo/SSA/Biologics | NANETS2023

Cabozantinib as salvage therapy for well differentiated grade 3 neuroendocrine tumors (G3 NETs)

Schnell Rylie R. , Eiring Rachel A. , Miller Morgan C. , McGarrah Patrick W. , Halfdanarson Thorvardur R.

Background: G3 NETs are a recently recognized entity and although the treatment recommendations largely follow those for grade 1 and 2 NETs, the outcomes of therapy are inferior. Little is known about the optimal therapy sequencing but small studies have suggested a benefit of multikinase inhibitors. Somatostatin analogs, PRRT and chemotherapy have all been reported to have activity but later lines of therapy are needed. In this study, we sought to evaluate the activity of cab...

ea0098c13 | Clinical – Chemo/SSA/Biologics | NANETS2023

Clinical characteristics and molecular profiling of patients with pancreatic mixed acinar-neuroendocrine carcinoma

Eslinger Cody , Seddighzadeh Bobak , Elsabbagh Zaid , Pai Rish , Hartley Chris , Starr Jason , Bekaii-Saab Tanios , Halfdanarson Thorvardur , Bassam Sonbol Mohamad

Background: Pancreatic acinar cell carcinoma (PACC) is a rare cancer, comprising less than 1% of all pancreatic cancers and often presents as a mixed malignancy with a neuroendocrine component. Limited data exists on its clinical and molecular characteristics. This retrospective study aims to provide additional insights to better understand and characterize the disease.Methods: Patients from the Mayo Clinic with pathology records denoting pancreatic acin...

ea0098o3 | Other | NANETS2023

Clinical characteristics of mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN): a single institution case series

Storandt Michael H. , Cowan Annie N. , Hubbard Joleen M. , Halfdanarson Thorvardur R. , Eun Lee Hee , Jin Zhaohui

Background: Gastroenteropancreatic mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN) is a rare entity consisting of two morphologically distinct populations of cells, one of which is neuroendocrine and one which is non-neuroendocrine. MiNENs typically contain high grade neuroendocrine carcinoma, conferring a poor prognosis. Due to the rarity of this diagnosis, data is limited and therefore, we sought to add to the current clinical understanding of this diagnosis.<p ...

ea0098o5 | Other | NANETS2023

Chromogranin A as Surveillance biomarker in Patients with cARcinoids (CASPAR)

Meng Qing , Halfdanarson Thorvardur R. , Bornhorst Joshua , Jann Henning , Shaheen Shagufta , Zhang Shi Run , Halperin Daniel M.

Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have highly heterogeneous growth rates, yielding broad ranges of radiographic imaging intervals in standard guidelines, creating uncertainty for clinicians and patients. Chromogranin A (CgA) is released by GEP-NET cells and has been associated with increased tumor burden. However, clinical utility of CgA measurement has been limited by the lack of prospective validation studies and by different sensitivity for...

ea0089t2 | Trials In Progress | NANETS2022

COMPOSE: Pivotal Phase III Trial for Well-Differentiated Aggressive Grade 2/3 Gastroenteropancreatic Neuroendocrine Tumors Comparing 177Lu-edotreotide with Best Standard of Care

R Halfdanarson Thorvardur , M Halperin Daniel , Reidy-Lagunes Diane , Kong Grace , Capdevila Jaume , Mailman Josh , Herrmann Ken , Srirajaskanthan Rajaventhan , Leyden Simone , Thevenet Thomas , Harris Philip

Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which frequently develop metastatic disease, represent an estimated 70% of NETs. There are limited treatment options with current standard therapies for well-differentiated aggressive grade 2 and grade 3 (Ki-67 index 15−55%) GEP-NETs; however, these may include somatostatin analogues; peptide receptor radionuclide therapy (PRRT); molecular targeted therapies (everolimus or sunitinib); chemotherapy; and ...

ea0089t4 | Trials In Progress | NANETS2022

Phase 1-2 Trial of Vesicular Stomatitis Virus Expressing Human Interferon-β and NIS (VSV-IFNβ-NIS), with Pembrolizumab, in Patients with Neuroendocrine Carcinoma

W. McGarrah Patrick , Naik Shruthi , R. Halfdanarson Thorvardur , Leventakos Konstantinos , Whye Peng Kah , J. Russell Stephen , A. Adjei Alex , R. Molina Julian

Background: Poorly differentiated neuroendocrine carcinoma (NEC) is an aggressive malignancy comprising both pulmonary and extrapulmonary primary sites. NEC includes both small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), as well as other neuroendocrine carcinomas arising from any primary organ. The optimal systemic therapy beyond first line platinum and etoposide is not established. There is a critical need to improve upon the median survival in th...

ea0090p117 | Endocrine-related Cancer | ECE2023

Pivotal phase III COMPOSE trial to compare lutetium (177Lu) edotreotide with best standard of care in patients with well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors

Capdevila Jaume , Halperin Daniel , Reidy-Lagunes Diane , Kong Grace , R Halfdanarson Thorvardur , Mailman Josh , Herrmann Ken , Srirajaskanthan Rajaventhan , Thevenet Thomas , Harris Philip

Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) represent an estimated 70% of NETs. GEP-NETs frequently develop metastatic disease with limited treatment options. For well-differentiated high grade 2 and 3 GEP-NETs, current therapies include peptide receptor radionuclide therapy (PRRT), somatostatin analogues, chemotherapy, cytoreduction, and molecular targeted therapies (everolimus, sunitinib). PRRT uses radiolabeled somatostatin analogues to selectively t...

ea0098c41 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

Spectrum of therapy-related clonal cytopenias and neoplasms after exposure to Lutetium-177-Dotatate

L Pritzl Stephanie , Kusne Yael , R Halfdanarson Thorvardur , Hobday Timothy , Bassam Sonbol Mohamad , Tuba Kendi Ayse , Mangaonkar Abhishek , Gangat Naseema , Shah Mithun , M Patnaik Mrinal

Background: Peptide receptor radionuclide therapy (PRRT) is a form of targeted systemic radiopharmaceutical therapy that has been approved for treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Persistent hematologic dysfunction is a recognized potential long-term toxicity after PRRT, including the development of hematologic malignancies and persistent cytopenias. Therapy-related myeloid neoplasms (t-MN) are a well-recognized entity that ...